(Q53895855)

22 May 2018

title

Levodopa or dopamine agonists, or deprenyl as initial treatment for Parkinson's disease. A randomized multicenter study. (English)

1 reference

22 May 2018

0 references

1 reference

1 reference

T Caraceni

1

1 reference

22 May 2018

M Musicco

series ordinal

2

1 reference

22 May 2018

publication date

1 April 2001

1 reference

22 May 2018

number of pages

8

1 reference

Parkinsonism and Related Disorders

inferred from page(s)

published in

1 reference

22 May 2018

volume

7

1 reference

22 May 2018

issue

2

1 reference

22 May 2018

page(s)

107-114

1 reference

22 May 2018

"On-off" effects in patients with Parkinson's disease on chronic levodopa therapy

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2800%2900023-7

7 January 2021

The occurrence of motor fluctuations in parkinsonian patients treated long term with levodopa: role of early treatment and disease progression

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2800%2900023-7

7 January 2021

Severity of Parkinson's disease is a risk factor for peak-dose dyskinesia

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2800%2900023-7

7 January 2021

Factors that influence the occurrence of response variations in Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2800%2900023-7

7 January 2021

Modification of Parkinson's disease by long-term levodopa treatment

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2800%2900023-7

7 January 2021

Initiation of levodopa therapy in parkinsonian patients should be delayed until the advanced stages of the disease

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2800%2900023-7

7 January 2021

Comparisons of therapeutic effects of levodopa, levodopa and selegiline, and bromocriptine in patients with early, mild Parkinson's disease: three year interim report. Parkinson's Disease Research Group in the United Kingdom

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2800%2900023-7

7 January 2021

A randomised controlled study comparing bromocriptine to which levodopa was later added, with levodopa alone in previously untreated patients with Parkinson's disease: a five year follow up.

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2800%2900023-7

7 January 2021

The Sydney Multicentre Study of Parkinson's disease: a randomised, prospective five year study comparing low dose bromocriptine with low dose levodopa-carbidopa

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2800%2900023-7

7 January 2021

Early combination therapy (bromocriptine and levodopa) does not prevent motor fluctuations in Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2800%2900023-7

7 January 2021

Effects of tocopherol and deprenyl on the progression of disability in early Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2800%2900023-7

7 January 2021

Selegiline as initial treatment in de novo parkinsonian patients

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2800%2900023-7

7 January 2021

Nonparametric Estimation from Incomplete Observations

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2800%2900023-7

7 January 2021

Comparison of therapeutic effects and mortality data of levodopa and levodopa combined with selegiline in patients with early, mild Parkinson's disease. Parkinson's Disease Research Group of the United Kingdom

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2800%2900023-7

7 January 2021

Comparative study of selegiline plus L-dopa-carbidopa versus L-dopa-carbidopa alone in the treatment of Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2800%2900023-7

7 January 2021

Selegiline in Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2800%2900023-7

7 January 2021

10.1016/S1353-8020(00)00023-7

Identifiers

DOI

1 reference

22 May 2018

PubMed ID

11248591

1 reference

22 May 2018